Critical Contrast: Celsion (NASDAQ:CLSN) Vs. Supernus Pharmaceuticals (NASDAQ:SUPN)
Critical Contrast: Celsion (NASDAQ:CLSN) Vs. Supernus Pharmaceuticals (NASDAQ:SUPN)
Celsion (NASDAQ:CLSN – Get Rating) and Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.
凯尔特(纳斯达克：CLSN-GET评级)和Supernus PharmPharmticals(纳斯达克：SUPN-GET评级)都是小盘医疗公司，但哪一家是优势投资？我们将根据分析师推荐的风险、估值、收益、盈利能力、机构所有权和股息对这两家公司进行对比。
Volatility & Risk
波动性与风险
Celsion has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.
Celsion的贝塔系数为2.27，这意味着其股价的波动性比标准普尔500指数高127%。相比之下，Supernus PharmPharmticals的贝塔系数为1.01，这意味着其股价的波动性比标准普尔500指数高1%。
Profitability
盈利能力
This table compares Celsion and Supernus Pharmaceuticals' net margins, return on equity and return on assets.
此表比较了Celsion和Supernus制药公司的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Celsion | -5,229.80% | -50.18% | -36.94% |
| Supernus Pharmaceuticals | 9.12% | 6.98% | 3.50% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 凯尔逊 | -5,229.80% | -50.18% | -36.94% |
| Supernus制药公司 | 9.12% | 6.98% | 3.50% |
Analyst Recommendations
分析师建议
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Celsion | 0 | 0 | 1 | 0 | 3.00 |
| Supernus Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 凯尔逊 | 0 | 0 | 1 | 0 | 3.00 |
| Supernus制药公司 | 0 | 0 | 2 | 0 | 3.00 |
Celsion currently has a consensus target price of $16.00, indicating a potential upside of 672.95%. Supernus Pharmaceuticals has a consensus target price of $41.00, indicating a potential upside of 18.39%. Given Celsion's higher possible upside, analysts plainly believe Celsion is more favorable than Supernus Pharmaceuticals.
Celsion目前的共识目标价为16.00美元，表明潜在上行672.95%。Supernus PharmPharmticals的共识目标价为41.00美元，表明潜在上涨18.39%。鉴于Celsion的上行可能性更高，分析师显然认为Celsion比Supernus PharmPharmticals更有利。
Earnings and Valuation
收益和估值
This table compares Celsion and Supernus Pharmaceuticals' top-line revenue, earnings per share and valuation.
该表格比较了Celsion和Supernus PharmPharmticals的营收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Celsion | $500,000.00 | 29.39 | -$20.77 million | N/A | N/A |
| Supernus Pharmaceuticals | $579.78 million | 3.20 | $53.42 million | $1.01 | 34.29 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 凯尔逊 | $500,000.00 | 29.39 | -2,077万元 | 不适用 | 不适用 |
| Supernus制药公司 | 5.7978亿美元 | 3.20 | 5,342万美元 | $1.01 | 34.29 |
Supernus Pharmaceuticals has higher revenue and earnings than Celsion.
Supernus PharmPharmticals的收入和收益高于Celsion。
Institutional and Insider Ownership
机构和内部人持股
13.0% of Celsion shares are held by institutional investors. Comparatively, 99.8% of Supernus Pharmaceuticals shares are held by institutional investors. 4.7% of Celsion shares are held by insiders. Comparatively, 8.7% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Celsion 13.0%的股份由机构投资者持有。相比之下，Supernus PharmPharmticals 99.8%的股份由机构投资者持有。Celsion 4.7%的股份由内部人士持有。相比之下，Supernus PharmPharmticals 8.7%的股份由内部人士持有。强大的机构持股表明，捐赠基金、大型基金管理公司和对冲基金相信，一只股票有望实现长期增长。
Summary
摘要
Supernus Pharmaceuticals beats Celsion on 8 of the 11 factors compared between the two stocks.
Supernus PharmPharmticals在两只股票比较的11个因素中有8个击败了Celsion。
About Celsion
关于Celsion
(Get Rating)
(获取评级)
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
Celsion公司是一家临床阶段生物技术公司，专注于基于DNA的免疫疗法、疫苗和定向化疗的开发和商业化。它的产品线包括GEN-1，一种用于卵巢癌局部治疗的基于DNA的免疫疗法；以及ThermoDox，一种阿霉素的专有热激活脂质体胶囊，正处于各种癌症适应症的开发阶段。该公司还拥有两项可行性阶段平台技术，用于开发基于核酸的免疫疗法、疫苗和其他抗癌DNA或RNA疗法。Celsion Corporation成立于1982年，总部设在新泽西州的劳伦斯维尔。
About Supernus Pharmaceuticals
关于Supernus制药公司
(Get Rating)
(获取评级)
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Supernus制药公司是一家生物制药公司，在美国专注于治疗中枢神经系统(CNS)疾病的产品的开发和商业化。它的商业产品是Trokendi XR，这是一种用于治疗癫痫和预防偏头痛的托吡酯缓释剂；奥克泰拉XR是一种缓释型奥卡西平，用于单一疗法治疗6至17岁的成人和儿童部分发作癫痫。该公司的商业产品还包括用于治疗6至17岁儿童注意缺陷多动障碍(ADHD)患者的选择性去甲肾上腺素再摄取抑制剂Qelbree；用于治疗晚期帕金森病(PD)患者运动能力低下或发作间歇的Apokyn；用于治疗帕金森病非发作患者的左旋多巴/卡比多巴的XADAGO；用于治疗成人颈部肌张力障碍和流涎的B型毒素产品Myobloc；用于治疗PD患者的运动障碍的GOCOVRI；以及用于治疗成人帕金森病和药物引起的锥体外系反应的Osmolex ER。此外，它的候选产品还包括用于治疗多动症的第三阶段临床试验已经完成的Qelbree(SPN-812)；用于防止帕金森病患者发作的晚期候选药物/设备组合产品SPN-830；用于治疗严重癫痫的第一阶段临床试验的候选新产品SPN-817；用于治疗难治性抑郁症的第二阶段临床试验候选产品SPN-820；以及处于治疗中枢神经系统疾病的临床前阶段的SPN-443和SPN-446。该公司通过药品批发商、专业药店营销和销售其产品。, 和分销商。该公司成立于2005年，总部设在马里兰州的罗克维尔。
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.
接受《凯尔逊日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Celsion和相关公司的最新新闻和分析师评级的每日简要摘要。